Showing results (461-470 of 653) with videos related to

Sort By:
Pageof 66
ESC Heart Failure|September 3, 2024
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetesGerasimos Filippatos, Stefan D Anker, George L Bakris, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Quételet (body mass) index and effects of dapagliflozin in chronic kidney diseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
Journal of the American Society of Nephrology : JASN|October 5, 2023
CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in AdultsLesley A Inker, Hocine Tighiouart, Ogechi M Adingwupu, et al.
Kidney International|November 1, 2025
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceSusan L Furth, Helen M Colhoun, Mehmet Kanbay, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
American Heart Journal|February 17, 2024
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and AlbuminuriaHiddo Jl Heerspink, Michele Provenzano, Priya Vart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 11, 2024
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysisPhil McEwan, Peter D Gabb, Jason A Davis, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
Clinical Kidney Journal|April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY populationNavdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Diabetes, Obesity & Metabolism|April 24, 2026
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY AnalysisJoão Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, et al.
Pageof 66